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ing the year follow-up were significantly higher for pa-
tients beginning treatment with a TCA than with a SSRI,
101.7 (SD 68.9) versus 81.6 (SD 63.5). Controlling for
confounders, males had fewer absences than females. La-
bor union members had significantly more absences than
did non-union workers. Initiating treatment with a TCA
resulted in nine additional absences compared to those
beginning treatment with a SSRI. CONCLUSIONS:
Treatment of depression with antidepressants appears to
lead to improved work outcomes through decreased ab-
senteeism. Initiating treatment with a SSRI as opposed to
a TCA may reduce the indirect costs of this disease in
terms of time away from work.
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Pharmacists have been working to help patients better
manage their health through disease state management
(DSM) programs. Because third party payers have been
reluctant to provide reimbursement for these services,
pharmacists are starting to bill the patient for payment. A
better understanding of who to target and how much to
charge for DSM programs would be beneficial to phar-
macists in developing and providing these programs. OB-
JECTIVE: The purpose of this study was to determine
what factors influence patient willingness to pay (WTP)
for a diabetes DSM program. METHODS: One hundred
fifty-five adult patients with diabetes were surveyed by
mail on the following factors to determine their effect on
WTP for a diabetes DSM program: patient satisfaction
with pharmacy services, health care utilization (hospital-
izations and emergency room visits), perceived need for
DSM, and sociodemographic factors. RESULTS: Patients
were willing to pay on average $27.80 (SD  $31.80) for
a one hour diabetes DSM consultation with the pharma-
cist. A regression model revealed that several factors sig-
nificantly (P  0.05) influenced patient WTP. Patients
who were likely to pay more for a diabetes DSM had a
greater perceived need for the service (P  0.004), had
more emergency room visits (P  0.0001), were more
likely to be male (P  0.009), were more likely to be
older (P  0.046), and had higher incomes (P  0.001)
This model was significant (P  0.0001) with 32 percent
of the variance explained. Although patient satisfaction
was not significant, it was positively correlated with
WTP. CONCLUSIONS: The project results may be use-
ful to pharmacists when determining the level of payment
for services, as well as targeting specific individuals and
tailoring DSM programs to meet diabetic patients’ needs.
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OBJECTIVE: The twofold purpose of the study was to:
1) develop health state descriptions of diabetic peripheral
neuropathy (DPN) and its complications for a new utility
instrument, and 2) use these descriptions to assess patient
preferences for health states associated with disease pro-
gression in DPN. METHODS: Development and pilot
testing of seven standardized health state scenarios de-
scribing disease progression and complications in DPN
have previously been presented. These seven states are
mild neuropathy, painful neuropathy, severe neuropathy,
mild ulcer, severe ulcer, minor amputation (toe) and ma-
jor amputation (below the knee). Patients between the
ages of 18 and 80 years were recruited from registries of
diabetic patients at the University of Washington Medi-
cal Center and the Seattle VA. Patients with a history of
DPN symptoms or complications were excluded. Each
patient completed a computer interview using the U-Titer
II utility measurement software. Both a rating scale (RS)
and a standard gamble (SG) technique were used to
quantify patient preferences for standardized descriptions
of the seven health states. RESULTS: 52 patients com-
pleted the 60-minute exercise. Overall, the mean utilities
for the seven health states were lower with the RS (0.86
to 0.27) when compared to the SG (0.87 to 0.61). The
preference scores followed a logical, decreasing order, in
accordance with severity, with the exception of the utility
for minor amputation being higher than for severe ulcer.
Neither previous knowledge of DPN nor demographic
characteristics were significant predictors of utility. CON-
CLUSIONS: This study has reported on the development
and evaluation of a new preference-based instrument for
use in DPN.
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Traditionally, bronchodilation with theophylline has
been a mainstay of treatment for persistent asthma. Cur-
rent treatment guidelines, however, call for reliance on
anti-inflammatory therapy and recommend that theo-
phylline and other long-acting bronchodilators be re-
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served for adjunctive therapy for patients not well-con-
trolled on antiinflammatories alone. OBJECTIVE: To
estimate the association between type of asthma mainte-
nance therapy (anti-inflammatory versus bronchodilator)
and total costs of asthma treatment. METHODS: Pa-
tients were selected from the Asthma Outcomes Registry
cohort if they had received either antiinflammatories (in-
haled steroids or cromones) or long-acting bronchodila-
tors (theophylline, long-acting beta-agonists, or ipratro-
pium), but not both, for at least one year prior to study
entry. Oral steroid dependent patients and those with in-
complete cost data during the baseline and follow-up in-
tervals (365 days before and after their enrollment in the
Registry, respectively) were excluded from the analysis.
The effect of anti-inflammatory versus bronchodilator
therapy was assessed by comparing the change (follow-
up minus baseline) in the logarithm of total costs of
asthma care. RESULTS: 446 patient met criteria for
study inclusion, including 351 treated with anti-inflam-
matories and 95 treated with bronchodilators. Geometric
mean costs during the baseline year were similar in the
anti-inflammatory and bronchodilator groups ($358 and
$351, respectively). In the follow-up year, geometric
mean costs declined by $149 (to $209) in the anti-inflam-
matory group compared to an increase of $19 (to $340)
in the bronchodilator group (P  0.0001). This treat-
ment effect was essentially unaltered after adjustment for
study site, age, sex, smoking, and comorbidity. CON-
CLUSION: These findings add support to current guide-
lines recommending reliance on anti-inflammatory ther-
apy to control asthma. The emergence of new therapeutic
agents to control inflammation may continue to reduce
the costs of treating this important disease.
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OBJECTIVES: The purpose of this study is to examine
the effect of treatment with abciximab versus eptifibatide
or tirofiban during angioplasty on hospital length of stay
(LOS). METHODS: Hospital billing data for PTCAs per-
formed over a one year period (July 1998 to June 1999)
was obtained from HCIA’s Clinical Pathways Database.
Data was collected for all patient discharges whose
records indicated use of abciximab, eptifibatide, or
tirofiban. Results are reported for 6,637 patients. Multi-
variate analysis was used to control for a wide range of
factors (patient demographics, insurance, health condi-
tions, admission and discharge information, as well as
hospital characteristics) which may influence LOS. Esti-
mation was conducted via a two-stage sample selection
model. The first stage of the analysis utilizes a probit re-
gression to determine the factors associated with the like-
lihood of receiving abciximab. In the second stage of the
analysis a negative binomial model is estimated for pa-
tient’s LOS, while controlling for unobserved factors that
are correlated with the patient’s likelihood of receiving
abciximab. RESULTS: The average LOS for PTCA pa-
tients was 3.48 days. After controlling for high risk indi-
cations and selection bias, PTCA patients who were given
abciximab had a significantly shorter LOS than patients
who were administered eptifibatide (0.981 fewer days
0.243) or patients who were administered tirofiban
(0.934 fewer days 0.251). CONCLUSIONS: Results of
this study indicate that there are potential cost off-sets
for hospitals that administer abciximab versus eptifi-
batide or tirofiban, given the significantly shorter LOS
associated with patients who received abciximab.
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Parkinson’s Disease is a chronic neurodegenerative ill-
ness, which affects a significant number of elderly indi-
viduals. Typically, the process onset is between 45 to 65
years old individuals. The prevalence of Parkinson’s in a
managed care environment is unknown. OBJECTIVES:
After controlling for appropriate case mix variables (e.g.
age, gender, presence of selected comorbidities etc.) what
is the epidemiology and what is the cost of illness of Par-
kinson’s disease in a large healthcare plan? METHODS:
This was a retrospective database cost of illness study
consisting of all members with Parkinson’s (ICD-9
332.0) from 7/1/95 to 6/30/98. Members were screened
for continuous enrollment, medical, and drug coverage.
Members diagnosed prior to 7/1/95 were stratified as
prevalent cases. Medicare patients were excluded. The
database consisted of all pharmaceutical, professional,
laboratory, radiology, and institutional claims for ap-
proximately 1.38 million individuals from 1993 to the
present. The risk of contracting Parkinson’s, and healthcare
consumption, were analyzed by patient residence. RE-
SULTS: Parkinson’s risk was highest in urban areas, 3.69
cases per 1,000, compared to 2.24 for rural, and 1.80 for
suburban. Mean cost per patient per year (pppy) for the
disease was $2,161. Medical costs were higher at diagnosis
and decreased with escalating drug therapy. Medical costs
began at $3,120 pppy, dropped to $124 pppy after 12
months, but rose to $1192 pppy after 3 years. Pharmacy
costs began at $220 pppy, rose to $520 pppy after 12
months, and were $1796 pppy after 3 years. CONCLU-
SIONS: The incidence and prevalence of Parkinson’s in
this study matched nationally reported rates. Treatment
patterns and cost followed a logical progression towards
more drug therapy as the disease apparently worsened.
